Impact of Altered Growth Factor Signalling on Endocrine Response in Breast Cancer and the Transition From ER+ to ER[minus Sign] Disease

Breast Cancer Online
doi 10.1017/s1470903104002585
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

Distinct Genes Related to Drug Response Identified in ER Positive and ER Negative Breast Cancer Cell Lines

PLoS ONE
Multidisciplinary
2012English

Neoadjuvant Palbociclib on ER+ Breast Cancer (N007): Clinical Response and EndoPredict Value

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2018English

Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells

Cancers
Cancer ResearchOncology
2010English

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

Loss of TBK1 Induces Epithelial-Mesenchymal Transition in the Breast Cancer Cells by ER Downregulation

Cancer Research
Cancer ResearchOncology
2013English

Overexpression of CXXC5 Is a Strong Poor Prognostic Factor in ER+ Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Estrogen Therapy Induces an Unfolded Protein Response to Drive Cell Death in ER + Breast Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Distinct P53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Clinical Cancer Research
Cancer ResearchOncology
2011English

Evaluating an ER Degrader for Breast Cancer

Cancer Discovery
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy